Urogen Pharma (URGN) Competitors $17.33 +0.49 (+2.91%) Closing price 04:00 PM EasternExtended Trading$17.33 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock URGN vs. NAMS, AMRX, CNTA, XENE, QURE, CGON, VKTX, APLS, IMVT, and KNSAShould you be buying Urogen Pharma stock or one of its competitors? The main competitors of Urogen Pharma include NewAmsterdam Pharma (NAMS), Amneal Pharmaceuticals (AMRX), Centessa Pharmaceuticals (CNTA), Xenon Pharmaceuticals (XENE), uniQure (QURE), CG Oncology (CGON), Viking Therapeutics (VKTX), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry. Urogen Pharma vs. Its Competitors NewAmsterdam Pharma Amneal Pharmaceuticals Centessa Pharmaceuticals Xenon Pharmaceuticals uniQure CG Oncology Viking Therapeutics Apellis Pharmaceuticals Immunovant Kiniksa Pharmaceuticals International Urogen Pharma (NASDAQ:URGN) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations. Do institutionals & insiders hold more shares of URGN or NAMS? 91.3% of Urogen Pharma shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 4.7% of Urogen Pharma shares are held by insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer URGN or NAMS? In the previous week, Urogen Pharma had 4 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 7 mentions for Urogen Pharma and 3 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.90 beat Urogen Pharma's score of 0.38 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NewAmsterdam Pharma 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, URGN or NAMS? Urogen Pharma has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, NewAmsterdam Pharma has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500. Which has higher earnings & valuation, URGN or NAMS? Urogen Pharma has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUrogen Pharma$90.40M8.87-$126.87M-$3.32-5.22NewAmsterdam Pharma$45.56M81.23-$241.60M-$1.62-20.28 Do analysts rate URGN or NAMS? Urogen Pharma presently has a consensus price target of $32.00, suggesting a potential upside of 84.65%. NewAmsterdam Pharma has a consensus price target of $42.00, suggesting a potential upside of 27.81%. Given Urogen Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Urogen Pharma is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Urogen Pharma 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80NewAmsterdam Pharma 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Is URGN or NAMS more profitable? Urogen Pharma has a net margin of -164.44% compared to NewAmsterdam Pharma's net margin of -259.07%. NewAmsterdam Pharma's return on equity of -27.27% beat Urogen Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Urogen Pharma-164.44% -97,487.15% -59.38% NewAmsterdam Pharma -259.07%-27.27%-25.00% SummaryUrogen Pharma beats NewAmsterdam Pharma on 9 of the 16 factors compared between the two stocks. Get Urogen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart URGN vs. The Competition Export to ExcelMetricUrogen PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$779.09M$3.37B$6.10B$10.65BDividend YieldN/A2.29%5.70%4.74%P/E RatioN/A21.7185.5527.59Price / Sales8.87477.40621.78138.47Price / CashN/A47.6737.7861.77Price / Book-82.5210.1413.136.76Net Income-$126.87M-$52.31M$3.30B$275.88M7 Day Performance-2.75%6.72%5.29%3.72%1 Month Performance-19.09%15.01%9.94%10.22%1 Year Performance32.19%29.34%87.78%35.86% Urogen Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)URGNUrogen Pharma3.9395 of 5 stars$17.33+2.9%$32.00+84.7%+35.6%$779.09M$90.40M0.00200Analyst ForecastNAMSNewAmsterdam Pharma2.9907 of 5 stars$29.38+3.3%$42.00+43.0%+81.5%$3.28B$45.56M-17.954Analyst ForecastAMRXAmneal Pharmaceuticals2.5864 of 5 stars$10.29+2.7%$12.00+16.7%+22.5%$3.23B$2.79B1,029.538,100Analyst ForecastCNTACentessa Pharmaceuticals3.2081 of 5 stars$23.73-2.1%$32.38+36.4%+49.1%$3.16B$6.85M-13.20200Analyst ForecastXENEXenon Pharmaceuticals2.9229 of 5 stars$40.22+0.2%$53.30+32.5%-3.5%$3.09B$7.50M-11.30210Trending NewsAnalyst ForecastAnalyst RevisionQUREuniQure3.5546 of 5 stars$55.79-4.4%$67.17+20.4%+986.7%$3.07B$27.12M-14.29500Trending NewsAnalyst ForecastAnalyst RevisionCGONCG Oncology2.3369 of 5 stars$40.12-0.4%$56.55+40.9%+7.1%$3.06B$551K-22.6761Analyst ForecastVKTXViking Therapeutics4.0319 of 5 stars$26.57+1.1%$86.42+225.2%-50.0%$2.97BN/A-17.2920Analyst ForecastAPLSApellis Pharmaceuticals4.1656 of 5 stars$23.04+1.8%$33.29+44.5%-8.2%$2.91B$754.65M-12.64770Analyst ForecastIMVTImmunovant1.9286 of 5 stars$16.67+3.4%$33.20+99.2%-45.2%$2.90BN/A-5.84120KNSAKiniksa Pharmaceuticals International3.6672 of 5 stars$38.87+0.1%$44.29+13.9%+60.6%$2.88B$529.33M971.84220Positive NewsAnalyst DowngradeGap Up Related Companies and Tools Related Companies NewAmsterdam Pharma Competitors Amneal Pharmaceuticals Competitors Centessa Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors uniQure Competitors CG Oncology Competitors Viking Therapeutics Competitors Apellis Pharmaceuticals Competitors Immunovant Competitors Kiniksa Pharmaceuticals International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:URGN) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored3 Major A.I. Threats That Could Upend the U.S. EconomyThe media's calling Artificial Intelligence a "revolution," but for many Americans, the real impact might actu...Goldco Precious Metals | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urogen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Urogen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
